PlainRecalls
FDA Drug Low Class III Terminated

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reported: January 25, 2017 Initiated: December 1, 2016 #D-0431-2017

Product Description

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reason for Recall

Failed Dissolution Specifications

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
6,800 cartons
Distribution
Nationwide in the USA and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 6,800 cartons.
Why was this product recalled?
Failed Dissolution Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on January 25, 2017. Severity: Low. Recall number: D-0431-2017.